A new radiopharmaceutical compound (131I-PR81) for radioimmunotherapy of breast cancer: labeling of antibody and its quality control.

摘要: PR81 is a monoclonal antibody that binds with high affinity to MUC1, which over expressed on breast and other tumors. The objective of this study was evaluate the application against MUC1 as radioimmunotherapeutical agent. Monoclonal (PR81) prepared, characterized, purified, labeled 131I. immunoreactivity radiolabeled mAb PR81with (the native protein), BSA-P20 (a 20 amino acid corresponding tandem repeat MUC1) MCF7 cell line were performed by RIA. In vitro stability in human serum determined thin layer chromatography (TLC). Cell toxicity internalization studies line, tissue biodistribution radioiodinated evaluated normal BALB/c mice at 4, 24 48 hrs. tumor imaging xenograft tumors 72 hr after complex injection. labeling efficiency found be 59.9% ± 7.9%. MAb-131I conjugates showed towards protein, line. product more than %50 hr. mAb-131I conjugate inhibited 80% growth cultured lines concentration up %60 internalized h. Biodistribution hrs post-injection no important accumulation observed vital organs. visualized sensitivity radioimmunoscintographical studies. These results show new radiopharmaceutical may considered promising candidate for therapy cancer.